Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Viral hepatitis, interferons

Cytokines and biological response modifiers represent a broad class of therapeutic agents that modify the hosts response to cancer or cancer therapies. The enormous body information about their clinical uses and their side effects is beyond the scope of this essay that can only give illustrative examples. For an up-to-date information the reader can resort to reference [5]. As many as 33 different interleukins are known and the list continues to grow IL-2 used in the treatment of kidney cancer is one example. Interferon alpha is used for chronic myelogenous leukeia, hairy cell leukaemia and Kaposi s sarcoma. Interferons are also used in the treatment of chronic infections such as viral hepatitis. Tumor necrosis factor (alpha), G/GM/M-CSF, and several other cellular factors are used in treatment of various cancers. Many of these cytokines produce serious side effects that limit their use. [Pg.268]

Niro GA, Rosina F, Rizzetto M (2005b) Treatment of hepatitis D. J Viral Hepat 12 2-9 Niro GA, Ciancio A, Gaeta GB, SmedUe A, Marrone A, OUvero A, Stanzione M, David E, Bran-caccio G, Fontana R, Perri F, AndriuUi A, Rizzetto M (2006) Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44 713-720... [Pg.238]

Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, de Man RA (2000) Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 7 428 34 Wong DK, Cheung AM, O Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 119 312-323... [Pg.242]

Interferon alfa is an antiviral agent that is effective in suppressing hepatitis B viral replication. Interferon alfa-2b and pegylated interferon alfa-2a are the only interferon therapies approved for the treatment of chronic hepatitis B. [Pg.353]

Ongoing clinical trials continue to assess the efficacy of recombinant interferon preparations in treating a variety of cancers. Some trials suggest that treatments are most effective when administered in the early stages of cancer development. rhIFN-as have also proven effective in the treatment of various viral conditions, most notably viral hepatitis. Hepatitis refers to an inflammation of the liver. It may be induced by toxic substances, immunological abnormalities, or by viruses (infectious hepatitis). The main viral causative agents are ... [Pg.228]

Woo, M. and Burnakis, T. 1997. Interferon-alpha in the treatment of chronic viral hepatitis-B and viral hepatitis... [Pg.239]

Medicinal thrombocytopenia can emerge under the use of different medicines, including interferon. The main mechanism of medicinal thrombocytopenia pathogenesis is assisted by the destruction of thrombocytes by the complement which is activated during antibody preparation. On withdrawal, the content of thrombocytes in blood is normalized. The formation of antibodies to thrombocytes in patients with viral hepatitis C occurs due to the destruction of membrane glycoproteins by the viruses. [Pg.419]

Treatment options for viral hepatitis include lamivu-dine, simple interferon alpha, polyethylene glycol-linked interferon (Peginterferon alfa-2a), and ade-fovir and ribavirin. Selected regimes have markedly improved response rates, but relapse is still common. [Pg.633]

Janssen, H.L., G. Gerken, V. Carreno, et al.. Interferon alfa for chronic hepatitis B infection increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology, 1999. 30 238 3. [Pg.184]

Poynard, T., V. Leroy, M. Cohard, et al., Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C effects of dose and duration. Hepatology, 1996. 24 778. [Pg.185]

Gottrand F, Michaud L, Guimber D, Ategbo S, Dubar G, Turck D, Farriaux JP. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996 155(12) 1031-4. [Pg.671]

Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002 56(6) 793-8. [Pg.672]

Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996 24(1) 38 17. [Pg.673]

Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci 2002 47(7) 1649-54. [Pg.673]

Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, de Lalla F. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998 28(3) 514—7. [Pg.673]

M. Guido, M. Rugge, L. Chemello, G. Leandro, G. Fattovich, G. Giustina, M. Cassaro, and A. Alberti, Liver stellate cells in chronic viral hepatitis the effect of interferon therapy, J. Hepatol. 24 301-307 (1996). [Pg.233]

Suicidal ideation or suicidal attempts have been reported in 1.3-1.4% of patients during interferon alfa treatment for chronic viral hepatitis or even within the 6 months after withdrawal (347,348), but the excess risk related to interferon alfa is not known. [Pg.673]

Scalori A, Apale P, Panizzuti F, Mascoli N, Pioltelli P, Pozzi M, Redaelli A, Roffi L, Mancia G. Depression during interferon therapy for chronic viral hepatitis early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000 12(5) 505-9. [Pg.709]

Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994 21(2) 241-3. [Pg.710]

IFNs were originally discovered more than 40 years ago by Isaacs and Lindemann because of their antiviral effects.Today interferons are used mainly in the treatment of infectious viral hepatitis B and C. IFNs control genes involved in antiviral responses. Mice lacking the IFN-responsive transcriptional activator and transmitter, STAT 1, are defenceless against viral infections. Three antiviral pathways are induced by IFNs (Fig. 6.12). [Pg.119]

This virus replicates only in the presence of hepatitis B. Interferon alfa is less effective than in other forms of viral hepatitis, giving sustained responses in about 15% of patients. [Pg.658]

See other pages where Viral hepatitis, interferons is mentioned: [Pg.312]    [Pg.312]    [Pg.42]    [Pg.231]    [Pg.232]    [Pg.242]    [Pg.113]    [Pg.416]    [Pg.418]    [Pg.221]    [Pg.208]    [Pg.161]    [Pg.179]    [Pg.179]    [Pg.180]    [Pg.180]    [Pg.181]    [Pg.183]    [Pg.1067]    [Pg.607]    [Pg.506]    [Pg.419]    [Pg.676]    [Pg.710]    [Pg.73]    [Pg.263]    [Pg.328]   
See also in sourсe #XX -- [ Pg.179 , Pg.180 , Pg.181 , Pg.182 ]



SEARCH



Hepatitis viral

Hepatitis, interferons

© 2024 chempedia.info